Eleni Stamellou
Overview
Explore the profile of Eleni Stamellou including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
28
Citations
106
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Buse M, Cheng M, Jankowski V, Lellig M, Sterzer V, Strieder T, et al.
iScience
. 2024 Mar;
27(3):109255.
PMID: 38444605
Tubular injury is the hallmark of acute kidney injury (AKI) with a tremendous impact on patients and health-care systems. During injury, any differentiated proximal tubular cell (PT) may transition into...
12.
Stamellou E, Saritas T, Froissart M, Kronenberg F, Stenvinkel P, Wheeler D, et al.
BMC Nephrol
. 2024 Feb;
25(1):60.
PMID: 38378456
Background: The consequences of chronic kidney disease (CKD) can be addressed with a range of pharmacotherapies primarily prescribed by nephrologists. More accurate information regarding future CKD-related pharmacotherapy requirements could guide...
13.
Chia-Gil A, Floege J, Stamellou E, Moeller M
J Nephrol
. 2024 Feb;
37(5):1405-1409.
PMID: 38300433
No abstract available.
14.
Inhibition of the glucocorticoid receptor attenuates proteinuric kidney diseases in multiple species
Stamellou E, Agrawal S, Siegerist F, Buse M, Kuppe C, Lange T, et al.
Nephrol Dial Transplant
. 2023 Dec;
39(7):1181-1193.
PMID: 38037533
Background: Glucocorticoids are the treatment of choice for proteinuric patients with minimal change disease (MCD) and primary focal segmental glomerulosclerosis (FSGS). Immunosuppressive as well as direct effects on podocytes are...
15.
Stamellou E, Seikrit C, Tang S, Boor P, Tesar V, Floege J, et al.
Nat Rev Dis Primers
. 2023 Nov;
9(1):67.
PMID: 38036542
IgA nephropathy (IgAN), the most prevalent primary glomerulonephritis worldwide, carries a considerable lifetime risk of kidney failure. Clinical manifestations of IgAN vary from asymptomatic with microscopic or intermittent macroscopic haematuria...
16.
Seikrit C, Schimpf J, Wied S, Stamellou E, Izcue A, Pabst O, et al.
J Nephrol
. 2022 Sep;
36(2):463-474.
PMID: 36107369
Background: A dysregulated 'gut-kidney axis' may contribute to immunoglobulin A nephropathy (IgAN). We studied whether IgAN patients have disturbed intestinal permeability. Methods: In a prospective, cross sectional, pilot study we...
17.
Seikrit C, Stamellou E, Rauen T, Floege J
Nephrol Dial Transplant
. 2022 Jul;
37(10):1786-1788.
PMID: 35881470
No abstract available.
18.
Buse M, Moeller M, Stamellou E
Front Physiol
. 2022 Jun;
13:933677.
PMID: 35755431
Acute Kidney injury is a major clinical problem associated with increased morbidity and mortality. Despite, intensive research the clinical outcome remains poor and apart from supportive therapy no other specific...
19.
Seikrit C, Rauen T, Stamellou E, Floege J
Nephrol Dial Transplant
. 2021 Jun;
36(Suppl 2):24-30.
PMID: 34153983
Immunoglobulin A nephropathy (IgAN) is the most common primary glomerular disease worldwide and since its first description extensive research has identified a number of key central pathogenetic contributors, including genetic,...
20.
Strieder T, Puelles V, Vogt M, Buhl E, Saritas T, Hausmann R, et al.
Cell Physiol Biochem
. 2021 Apr;
55(S4):1-12.
PMID: 33851800
Background/aims: Podocytes are lost in most glomerular diseases, leading to glomerulosclerosis and progressive kidney disease. It is generally assumed, that podocytes are exposed to the filtration flow and thus to...